Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43916   clinical trials with a EudraCT protocol, of which   7306   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-005093-38
    Sponsor's Protocol Code Number:GDS02C/V503-004
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-05-17
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-005093-38
    A.3Full title of the trial
    An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16-to-26 Year-Olds)
    Ensayo clínico abierto de fase III para evaluar la inmunogenicidad y la tolerabilidad de Gardasil®9 (vacuna polivalente de partículas similares al virus (VLP) L1 frente al virus del papiloma humano [VPH]) en mujeres adultas (de 27 a 45 años) en comparación con mujeres adultas jóvenes (de 16 a 26 años)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old.
    Ensayo clínico para evaluar la respuesta de anticuerpos y tolerabilidad de GARDASIL®9 en mujeres de 27 a 45 años en comparación con mujeres de 16 a 26 años.
    A.4.1Sponsor's protocol code numberGDS02C/V503-004
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorSanofi Pasteur MSD S.N.C
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportSanofi Pasteur MSD S.N.C.
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationSanofi Pasteur MSD
    B.5.2Functional name of contact pointStudy Management Head
    B.5.3 Address:
    B.5.3.1Street Address162 avenue Jean Jaures
    B.5.3.2Town/ cityLyon Cedex 07
    B.5.3.3Post code69367
    B.5.3.4CountryFrance
    B.5.4Telephone number34900834223
    B.5.6E-mailRegistroEspanolDeEstudiosClinicos@druginfo.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name GARDASIL®9
    D.2.1.1.2Name of the Marketing Authorisation holderSanofi Pasteur MSD SNC
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHuman Papillomavirus 9-valent Vaccine, Recombinant
    D.3.2Product code V503
    D.3.4Pharmaceutical form Suspension for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntramuscular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 6 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB22591
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number30
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 11 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB22592
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 16 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB22593
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number60
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 18 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB22594
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 31 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB91674
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 33 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB91675
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 45 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB91676
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman Papillomavirus Type 52 L1 protein
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB91677
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN
    D.3.9.3Other descriptive nameHUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN
    D.3.9.4EV Substance CodeSUB91678
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by HPV Types 6,11,16,18,31,33,45,52,58
    Prevención de los cánceres de cuello uterino, vulva, vagina y ano y de lesiones precancerosas relacionadas, así como de lesiones genitales externas, anomalías en la citología vaginal y la infección persistente causada por los tipos 6, 11, 16, 18, 31, 33, 45, 52 y 58 del VPH
    E.1.1.1Medical condition in easily understood language
    Prevention of cervical,vulvar,vaginal, and anal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus
    Prevención cánceres de cuello uterino, vulva, vagina y ano, lesiones precancerosas relacionadas y lesiones genitales externas, anomalías en la citología vaginal e infección persistente por VPH
    E.1.1.2Therapeutic area Diseases [C] - Virus Diseases [C02]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level LLT
    E.1.2Classification code 10052182
    E.1.2Term Vaginal papilloma
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10066416
    E.1.2Term Vulvovaginal human papilloma virus infection
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level HLT
    E.1.2Classification code 10033724
    E.1.2Term Papilloma viral infections
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate that the administration of GARDASIL®9 in 27- to 45 year old women induces non inferior geometric mean titres (GMTs) for serum anti-HPV 16, 18, 31, 33, 45, 52, and 58 compared with 16- to 26-year-old women.
    Demostrar que la administración de GARDASIL®9 en mujeres de 27 a 45 años de edad induce medias geométricas de los títulos (MGT) de anticuerpos séricos anti-VPH 16, 18, 31, 33, 45, 52 y 58 no inferiores a las que se observan en mujeres de 16 a 26 años de edad.
    E.2.2Secondary objectives of the trial
    To evaluate the safety/tolerability of GARDASIL®9 in 27- to 45-year-old women compared with 16 to 26-year-old women
    To demonstrate that GARDASIL®9 is immunogenic with respect to HPV types 16, 18, 31, 33, 45, 52, and 58 in 27- to 45-year-old women
    Evaluar la seguridad y la tolerabilidad de GARDASIL®9 en mujeres de 27 a 45 años en comparación con mujeres de 16 a 26 años de edad.
    Demostrar que GARDASIL®9 es inmunógena para los tipos de VPH 16, 18, 31, 33, 45, 52 y 58 en mujeres de 27 a 45 años de edad.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    To be included in the study and to receive the first study vaccination, subjects must meet all inclusion criteria. For items with an asterisk (*), if the subject does not meet these inclusion criteria, the Day 1 visit may be rescheduled for a time when these criteria can be met.
    1. Independent Ethics Committee (IEC)-approved written informed consent form (ICF) and privacy language as per national regulations must be obtained from the subject and/or from the subject?s parent(s) or legal guardian(s) prior to any study-related procedures (including discontinuation of prohibited medication, if applicable); assent (for minor subjects) by the subject is given as required by local law.
    2. Subject is a woman between the ages 16 years and 0 days and 45 years and 364 days as of first vaccination.
    3. Subject is judged to be in good physical health on the basis of medical history, physical examination (if deemed necessary), and laboratory testing.
    4. Subject, or subject's parent or guardian, is able to understand and adhere to the study procedures (e.g., is not planning to relocate far from the investigational centre during the study period); is able to read, understand, and complete the vaccination report card (VRC); is able to understand the risks involved with the study; and voluntarily agrees to participate in the study by giving written informed consent.
    5. For sexually active women: Subject has used effective contraception for 2 weeks prior to enrolment and agrees to use effective contraception through Month 7 of the study. Effective contraception includes oral contraceptives, injection or implant contraception, hormonal patch, intra-uterine device, sterilization or abstinence. Emergency contraception is not considered effective contraception for enrolment into the study.
    6.* Subject has had no temperature >=37.8°C or 100.0°F (oral) within 24 hours prior to the first injection.
    7. Subject agrees to provide study personnel with a primary telephone number as well as an alternate telephone number for follow-up purposes.
    Para poder ser incluidas en el estudio y recibir la primera vacunación del estudio, las pacientes deberán cumplir todos los criterios de inclusión. En cuanto a los puntos marcados con un asterisco (*), si la paciente no cumple estos criterios de inclusión, se podrá posponer la visita del día 1 a un momento en que se cumplan estos criterios.
    1. Antes de llevar a cabo los procedimientos del estudio (incluida la suspensión de medicamentos prohibidos, si procede), se obtendrán de la paciente, o de sus padres o tutores legales, un documento de consentimiento informado (DCI) y un texto sobre confidencialidad conforme a la normativa nacional aprobados por el Comité de Ética Independiente (CEI); si la legislación local lo exige, se aportará el asentimiento de la paciente (si es menor de edad).
    2. La paciente es una mujer de entre 16 años y 0 días y 45 años y 364 días de edad en el momento de la vacunación.
    3. La paciente se encuentra en buen estado de salud física, a tenor de sus antecedentes médicos, la exploración física (si se considera necesaria) y los análisis clínicos.
    4. La paciente (o sus padres o tutores) es capaz de comprender y cumplir los procedimientos del estudio (p. ej., no tiene previsto mudarse lejos del centro de investigación durante el período del estudio); puede leer, comprender y cumplimentar la tarjeta de vacunación (TV); entiende los riesgos que comporta el estudio; y accede voluntariamente a participar en el estudio, para lo que otorga su consentimiento informado por escrito.
    5. Mujeres sexualmente activas: La paciente ha utilizado un método anticonceptivo eficaz durante 2 semanas antes del reclutamiento y se compromete a utilizarlo hasta el mes 7 del estudio. Entre los métodos anticonceptivos eficaces figuran anticonceptivos orales, anticonceptivos inyectables o implantables, parche hormonal, dispositivo intrauterino, esterilización o abstinencia. Los anticonceptivos de emergencia no se consideran métodos eficaces a efectos del reclutamiento para el estudio.
    6. * La paciente no ha tenido fiebre >=37,8°C (bucal) en las 24 horas previas a la primera inyección.
    7. La paciente accede a facilitar al personal del estudio un número de teléfono principal y uno alternativo con fines de seguimiento.
    E.4Principal exclusion criteria
    To be included and receive the first study vaccination, subjects should not have any exclusion criteria. For items with an asterisk (*), if the subject meets these exclusion criteria, the Day 1 visit may be rescheduled for a time when these criteria are not met.
    1. Subject has a history of an abnormal Pap test or abnormal cervical biopsy results (showing cervical intraepithelial neoplasia or worse) or cervical disease (i.e., surgical treatment for cervical lesions).
    2. Subject has history of genital warts, Vulvar Intraepithelial Neoplasia or Vaginal Intraepithelial Neoplasia.
    3. Subject has a history of a positive test for HPV.
    4. Subject has a history of known prior vaccination with an HPV vaccine, i.e., received a marketed HPV vaccine, or has participated in an HPV vaccine clinical study and has received either active agent or placebo.
    5. Subject is pregnant (as determined by urine pregnancy test).
    6. Subject is, at the time of signing ICF, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems as a result of alcohol use.
    7. Subject has a history of severe allergic reaction, including known allergy to any vaccine component, including aluminum, yeast, or BENZONASE® (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]) (e.g., swelling of the mouth and throat, difficulty breathing, hypotension or shock) that met the criteria for serious adverse experiences defined in this protocol.
    8. Subject has had a splenectomy, or is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukaemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune or immunosuppressive condition, or has a history of any disease, which, in the investigator?s opinion, may confound the results of the study or pose an additional risk to the subject.
    9. Subject is receiving or has received in the year prior to enrolment the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (tumour necrosis factor-? antagonists, monoclonal antibody therapies (including rituximab [Rituxan]), intravenous gamma globulin, antilymphocyte sera, or other therapy known to interfere with the immune response. With regard to systemic corticosteroids, a subject will be excluded if she is currently receiving steroid therapy, has recently (defined as within 2 weeks of enrolment) received such therapy, or has received 2 or more courses of high dose corticosteroids (>=20mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to enrolment. Subjects using inhaled, nasal, or topical corticosteroids are considered eligible for the study.
    10. Subject has received any immune globulin or blood-derived product within the 3 months prior to the Day 1 vaccination, or plans to receive any such product during Day 1 through Month 7 of the study.
    11. * Subject has received non-replicating (inactivated) vaccines within 14 days prior to the Day 1 vaccination or has received replicating (live) vaccines within 21 days prior to the Day 1 vaccination.
    12. Subject has thrombocytopenia or other coagulation disorder that would contraindicate intramuscular injections.
    13. Subject is concurrently enrolled in a clinical study of investigational agent.
    14. Subject has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the subject?s participation for the full duration of the study, such that it is not in the best interest of the subject to participate.
    Para poder ser incluidas y recibir la primera vacunación del estudio, las pacientes no deben cumplir ninguno de los criterios de exclusión. En cuanto a los puntos marcados con un asterisco (*), si la paciente cumple estos criterios de exclusión, se podrá posponer la visita del día 1 a un momento en que no se cumplan estos criterios.
    1. La paciente tiene antecedentes de anomalías en una citología o una biopsia de cuello uterino (que evidencien una neoplasia intraepitelial del cuello uterino o algo peor) o de enfermedades del cuello uterino (es decir, tratamiento quirúrgico para lesiones cervicales).
    2. La paciente tiene antecedentes de verrugas genitales, neoplasia intraepitelial vulvar o neoplasia intraepitelial vaginal.
    3. La paciente tiene antecedentes de análisis positivos para el VPH.
    4. La paciente tiene antecedentes de vacunación conocida con una vacuna contra el VPH, es decir, ha recibido una vacuna contra el VPH comercializada o ha participado en un estudio clínico de vacunas contra el VPH y ha recibido fármaco activo o placebo.
    5. La paciente está embarazada (as determinado por una prueba de embarazo en orina).
    6. La paciente, en el momento de la firma del DCI, consume drogas o tiene antecedentes recientes (en el último año) de abuso o dependencia de las drogas o el alcohol. Se define como alcohólicos a las personas que beben a pesar de los problemas sociales, interpersonales o legales recurrentes que les genera este consumo.
    7. La paciente tiene antecedentes de una reacción alérgica grave, incluida una alergia conocida a algún componente de la vacuna, como el aluminio, la levadura o BENZONASE® (nucleasa, Nycomed [se utiliza para eliminar restos de ácidos nucleicos de esta y otras vacunas]) (p. ej., inflamación de la boca y la garganta, dificultad para respirar, hipotensión o choque) que cumplen los criterios de acontecimientos adversos definidos en este protocolo.
    8. La paciente se ha sometido a una esplenectomía, está inmunodeprimida o se le ha diagnosticado una inmunodeficiencia congénita o adquirida, una infección por el VIH, linfoma, leucemia, lupus eritematoso sistémico, artritis reumatoide, artritis reumatoide juvenil, enteropatía inflamatoria u otra enfermedad autoinmunitaria o inmunodepresora, o tiene antecedentes de alguna enfermedad que, en opinión del investigador, podría aportar confusión a los resultados del estudio o suponer un riesgo adicional para la paciente.
    9. La paciente recibe o ha recibido en el año previo al reclutamiento los siguientes tratamiento inmunodepresores: radioterapia, ciclofosfamida, azatioprina, metotrexato, algún quimioterápico, ciclosporina, leflunomida (antagonistas de factor de necrosis tumoral ?, tratamientos a base de anticuerpos monoclonales (como rituximab [Rituxan]), gammaglobulina intravenosa, sueros antilinfocitarios u otros tratamientos que se sepa que interfieren con la respuesta inmunitaria. En relación con los corticosteroides sistémicos, quedarán excluidas las pacientes que estén recibiendo tratamiento con esteroides, lo hayan recibido recientemente (en las 2 semanas previas al reclutamiento) o que hayan recibido 2 o más ciclos de corticosteroides en dosis altas (>=20 mg/día de prednisona [o equivalente] por vía oral o parenteral) de al menos 1 semana de duración en el año previo al reclutamiento. Las pacientes que utilicen corticosteroides inhalados, nasales o tópicos se consideran aptas para el estudio.
    10. La paciente ha recibido inmunoglobulinas o hemoderivados en los 3 meses previos a la vacunación del día 1 o tiene previsto recibir algún producto de este tipo entre el día 1 y el mes 7 del estudio.
    11. * La paciente ha recibido vacunas que no se multiplican (inactivadas) en los 14 días previos a la vacunación del día 1 o ha recibido vacunas que se multiplican (elaboradas con microorganismos vivos) en los 21 días previos a la vacunación del día 1.
    12. La paciente tiene trombocitopenia u otro trastorno de la coagulación que supone una contraindicación para las inyecciones intramusculares.
    13. La paciente participa en la actualidad en un estudio clínico de un fármaco en investigación.
    14. La paciente tiene antecedentes o indicios actuales de enfermedades, tratamientos, anomalías analíticas u otras circunstancias que podrían aportar confusión a los resultados o interferir con la participación de la paciente a lo largo de todo el estudio, de modo que lo mejor para ella es que no participe.
    E.5 End points
    E.5.1Primary end point(s)
    The primary immunogenicity endpoints are the cLIA GMTs to HPV 16, 18, 31, 33, 45, 52 and 58.
    Las variables principales de inmunogenicidad son las medias geométricas de los títulos (MGT) de anticuerpos anti-VPH 16, 18, 31, 33, 45, 52 y 58 determinadas por cLIA (inmunoensayo competitivo Luminex® )
    E.5.1.1Timepoint(s) of evaluation of this end point
    at 4 weeks after Dose 3.
    4 Semanas después de la Dosis 3
    E.5.2Secondary end point(s)
    The secondary immunogenicity endpoints are:

    the cLIA seroconversion percentages to HPV 16, 18, 31, 33, 45, 52 and 58 in 27- to 45-year-old women.

    the cLIA GMTs and the cLIA seroconversion percentages to each of HPV 6,11,16,18,31,33,45,52, and 58 in 16- to 26-year-old women and 27- to 45 year-old women.

    The Safety assessment will focus on injection site adverse reactions and elevated temperatures reported on the VRC. SAEs, pregnancy, and pregnancy-related events will be collected.
    Las variables secundarias de inmunogenicidad son:
    El porcentaje de seroconversión frente a VPH 16, 18, 31, 33, 45, 52 y 58 determinado por cLIA en mujeres entre 27 y 45 años
    E.5.2.1Timepoint(s) of evaluation of this end point
    Immunogenicity: by 4 weeks after Dose 3.
    Safety: for injection Day 1 to Day 5 post-vaccination and systemic AEs Day 1 to Day 15 post-vaccination. For SAEs, pregnancy, and pregnancy-related events , from the time the ICF is signed through 1 month following the last vaccination
    Inmunogenicidad: 4 semanas después de la dosis 3.
    Seguridad: Reacciones adversas en el lugar de inyección que se produzcan entre el día 1 y el día 5 después de una vacunación y acontecimientos adversos sistémicos en los 14 días posteriores a una vacunación. Para Acontecimientos Adversos Graves, embarazos y eventos relacionados con embarazos, desde el momento de la firma del documento de consentimiento informado hasta un mes después de la última vacunación.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis Yes
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    This is an international, multicentre; open-label, immunogenicity and tolerability study of GARDASIL®9 in 16- to 45-year-old women.
    Este es un ensayo clínico internacional, multicéntrico, abierto para evaluar la inmunogenicidad y la tolerabilidad de Gardasil®9 en mujeres 16 a 45 años de edad.
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    diferente grupo de edad
    different age group
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA22
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study will be defined as the end of data collection including availability of serology results.
    El final del estudio se definirá como el final de la recogida de datos incluyendo la disponibilidad de los resultados de serología.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months18
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months18
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 150
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 150
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1050
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Yes
    F.3.2Patients No
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state320
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1200
    F.4.2.2In the whole clinical trial 1200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-06-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-06-17
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-01-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA